Bernstein Upgrades Summit Therapeutics to Market Perform, Raises Price Target to $11.9

Benzinga · 4d ago
Bernstein analyst Jeffrey Walch upgrades Summit Therapeutics (NASDAQ:SMMT) from Underperform to Market Perform and raises the price target from $9.8 to $11.9.